-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
1 day Ago By ABMN Staff
Bank of New York Mellon Corp raised its holdings in Mind Medicine (MindMed) Inc. ( NASDAQ:MNMD – Free Report ) by 472.7% during the 2nd quarter, Holdings Channel.
com reports. The institutional investor owned 246,208 shares of the company’s stock after purchasing an additional 203,216 shares during the quarter. Bank of New York Mellon Corp’s holdings in Mind Medicine (MindMed) were worth $1,775,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tidal Investments LLC bought a new stake in Mind Medicine (MindMed) in the first quarter valued at approximately $1,698,000. Jump Financial LLC raised its stake in Mind Medicine (MindMed) by 8.
3% in the fourth quarter. Jump Financial LLC now owns 36,826 shares of the company’s stock valued at $135,000 after buying an additional 2,826 shares during the period. Janus Henderson Group PLC bought a new position in shares of Mind Medicine (MindMed) during the first quarter worth approximately $8,964,000.
Virtu Financial LLC bought a new position in shares of Mind Medicine (MindMed) during the first quarter worth approximately $239,000. Finally, Scotia Capital Inc. bought a new position in shares of Mind Medicine (MindMed) during the fourth quarter worth approximately $441,000.
Institutional investors own 27.91% of the company’s stock. Mind Medicine (MindMed) Stock Performance Shares of Mind Medicine (MindMed) stock opened at $6.
08 on Thursday. Mind Medicine has a one year low of $2.41 and a one year high of $12.
22. The firm has a market capitalization of $436.98 million, a price-to-earnings ratio of -2.
07 and a beta of 2.53. The business has a 50-day simple moving average of $7.
09 and a 200 day simple moving average of $8.07. The company has a debt-to-equity ratio of 0.
12, a current ratio of 5.92 and a quick ratio of 5.92.
Insider Buying and Selling at Mind Medicine (MindMed) In other news, CEO Robert Barrow sold 15,659 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $7.22, for a total value of $113,057.
98. Following the transaction, the chief executive officer now owns 564,543 shares in the company, valued at approximately $4,076,000.46.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . In related news, insider Dan Karlin sold 6,925 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $7.
22, for a total value of $49,998.50. Following the sale, the insider now owns 351,527 shares of the company’s stock, valued at approximately $2,538,024.
94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Also, CEO Robert Barrow sold 15,659 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, June 25th.
The stock was sold at an average price of $7.22, for a total transaction of $113,057.98.
Following the completion of the sale, the chief executive officer now directly owns 564,543 shares in the company, valued at approximately $4,076,000.46. The disclosure for this sale can be found here .
Company insiders own 2.26% of the company’s stock. Wall Street Analyst Weigh In A number of brokerages have recently weighed in on MNMD.
Robert W. Baird began coverage on Mind Medicine (MindMed) in a research note on Tuesday, May 28th. They set an “outperform” rating and a $27.
00 target price on the stock. HC Wainwright increased their target price on Mind Medicine (MindMed) from $35.00 to $55.
00 and gave the stock a “buy” rating in a research note on Thursday, August 29th. Roth Mkm began coverage on Mind Medicine (MindMed) in a research note on Wednesday, July 24th. They set a “buy” rating and a $36.
00 target price on the stock. Roth Capital upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Wednesday, July 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Mind Medicine (MindMed) in a research report on Friday, June 21st.
Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mind Medicine (MindMed) presently has an average rating of “Buy” and an average price target of $25.
38. Read Our Latest Research Report on Mind Medicine (MindMed) Mind Medicine (MindMed) Profile ( Free Report ) Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Featured Stories Want to see what other hedge funds are holding MNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mind Medicine (MindMed) Inc. ( NASDAQ:MNMD – Free Report ).
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter ..
